自身免疫性肝炎与药物性肝损伤的鉴别诊断和处理
- 1、下载文档前请自行甄别文档内容的完整性,平台不提供额外的编辑、内容补充、找答案等附加服务。
- 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
- 3、如文档侵犯您的权益,请联系客服反馈,我们会尽快为您处理(人工客服工作时间:9:00-18:30)。
自身免疫性肝炎与药物性肝损伤:鉴别诊断和处理
苗琪马雄
[关键词] 肝炎,自身免疫性; 肝炎,慢性,药物性;
鉴别诊断;治疗
Differential diagnosis and therapy for autoimmune hepatitis and
MIAO QiMA Xiong
drug-induced liver injury
[Keywords] Hepatitis,autoimmune;Hepatitis,chronic,drug-Induced;
Differential diagnosis;Therapy
[First author's address] Department of Gastroenterology,
Renji Hospital, Shanghai Jiaotong University School of Medicine
Shanghai Institute of Digestive Disease, Shanghai 200001, China
Corresponding author: MA Xiong, Email:maxiongmd@hotmail.
com
自身免疫性肝炎(AIH)是由异常自身免疫反
应介导的肝实质炎症性病变,多发于女性,以高丙
种球蛋白血症、血清自身抗体阳性和对免疫抑制剂
治疗应答为特点。药物性肝损伤(drug-induced liver
injury, DILI)是与用药相关的肝功能损伤,同样多见
于女性,有时可出现自身抗体阳性,严重病例需免
疫抑制剂治疗。两者究竟存在怎样的关系,如何在
初诊时予以鉴别和适当治疗是临床医生需要重视的
问题。
@@ 一、AIH和DILI的关系
@@ 在临床工作中存在这样的现象:DILI患者恢复
后再次使用相同或相似的药物可出现AIH样表现。
Lucena等[1]从西班牙药物性肝损中心选取9例两次
出现DILI的患者(9/742),其中8例第二次肝损伤的
类型和第一次相同(肝细胞型为主),4例患者两次
肝损伤前后使用药物的结构相似,2例作用靶点相似。
10.3760/cma.j.issn. 1007-3418.2012.05.003
作者单位:200001 上海交通大学医学院附属仁济医院消化科
上海市消化疾病研究所
激素对两者均有
@@[1] Lucena MI, Kaplowitz N, Hallal H, et al. Recurrent drug-induced liver injury (DILI) with different drugs in the Spanish registry: the dilemma of the relationship to autoimmune hepatitis. J Hepatol, 2011, 55: 820-827.
@@[2] Alvarez F, Berg PA, Bianchi FB, et al. International autoimmune hepatitis group repot: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol, 1999, 31: 929-938.@@[3] Hennes EM, Zeniya M, Czaja A J, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology, 2008, 48: 169-176.
@@[4] Weiler-Normann C, Schramm C. Drug induced liver injury and its relationship to autoimmune hepatitis. J Hepatol, 2011, 55: 747- 749.
@@[5] Czaja AJ. Drug-induced autoimmune-like hepatitis. Dig Dis Sci, 2011, 56: 958-976.
@@[6] Bjōrnsson E, Talwalkar J, Treeprasertsuk S, et al. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology, 2010, 51: 2040-2048.
@@[7] Bogdanos DP, Mieli-Vergani G, Vergani D. Autoantobodies and their antigens in autohmmune hepatitis. Semin Liver Dis, 2009, 29: 241- 253.
@@[8] Lecoeur S, André C, Beaune PH. Tienilic acid-induced autoimmune hepatitis: anti-liver and-kidney microsomal type 2 autoantibodies recognize a three-site conformational epitope on cytochrome P4502C9. Mol Pharmacol, 1996, 50: 326-333.@@[9] Zimmerman HJ. Drug-induced liver disease. Clin Liver Dis, 2000, 4: 73-96.
@@[10] Efe C, Purnak T, Ozaslan E, et al. Drug-induced autoimmune hepatitis caused by anti-tumor necrosis factor α agents. Hepatplogy, 2010, 52: 2246-2247.
@@[11] von Kalckreuth V, Lohse AW, Schramm C. Unmasking autoimmune
hepatitisunder immunomodulatory treatment of multiple sclerosis not only beta interferon. Am J Gastroenterol, 2008, 103: 2147-2148.@@[12] Watkins PB, Seeff LB. Drug-induced liver injury: summary of a single topic clinical research conference. Hepatology, 2006, 43:618- 631.
@@[13] Fontana R J, Seeff LB, Andrade RJ, et al. Standardization of nomenclature and causality assessment in drug-induced liver injury:. summary of a clinical research workshop. Hepatology, 2010, 52: 730-742.
@@[14] Suzuki A, Brunt EM, Kleiner DE, et al. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology, 2011, 54:931-939.@@[15] Lewis JH. Diagnosis: liver biopsy differentiates DILI from autoimmune hepatitis. Nat Rev Gastroenterol Hepatol, 2011, 8: 540- 542.
@@[16] Manns MP, Czaja AJ, Gorham HD, et al. Diagnosis and mamagement of autoimmune hepatitis. Hepatology, 2010, 51: 2193-2213.
@@[17] Bj(o)rnsson E, Kalaitzakis E, Av Klinteberg V, et al. Long-term follow-up of patients with mild to moderate drug-induced liver injury. Aliment Pharmacol Ther, 2007, 26: 79-85.
@@[18] Bj(o)rnsson E, Davidsdottir L. The long-term follow-up after idiosyncratic drug-induced liver injury with jaundice. J Hepatol, 2009, 50: 511-517.
2012-02-15